Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAF V600E ‐associated thyroid carcinoma

1 May 2024

Abstract excerpt

Abstract Background BRAF V600E is the most common genetic mutation in differentiated thyroid cancer (DTC) occurring in 60% of patients and drives malignant tumour cell phenotypes including proliferation, metastasis and immune‐escape. BRAF V600E ‐mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendency to radioactive iodine (RAI) refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers in Disease Mechanisms
Share to Cancer-related Molecular Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38797942
DOI: 10.1002/ctm2.1694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAF V600E ‐associated thyroid carcinomaPMID 38797942Read ↗

[Application of BRAF in the diagnosis and treatment of thyroid papillary carcinoma].Semantic proximity Read ↗

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinomaSemantic proximity Read ↗

BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.Semantic proximity Read ↗

Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

The role of BRAF in the pathogenesis of thyroid carcinoma.Semantic proximity Read ↗

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.Semantic proximity Read ↗

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationSemantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.Semantic proximity Read ↗

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.